Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease

Source: Taking Aim at HER3 in Lung Cancers Resistant to EGFR Inhibitors
In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated non-small-cell lung cancer, including the evolving treatment landscape for disease resistant to standard-of-care EGFR TKI inhibitors.
person default
Elise Hitron, MSN, FNP-C
Frank Schneider, MD
person default
Conor Ernst Steuer, MD
Released: January 26, 2022

In this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated NSCLC. Topics include:

  • Testing for targetable biomarkers
  • Talking with patients about biomarker testing
  • Frontline therapy for EGFR-positive NSCLC
  • Resistance to front-line osimertinib
  • Treatment of EGFR TKI–resistant disease, including the emerging antibody–drug conjugate patritumab deruxtecan
  • HER3 protein testing
  • Pathology considerations
  • Nursing considerations
  • Interdisciplinary communication

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Information on this Educational Activity

Faculty

Elise Hitron, MSN, FNP-C

Nurse Practitioner
Phase I Clinical Trials at Winship Cancer Institute
Atlanta, Georgia

Elise Hitron, MSN, FNP-C, has no relevant conflicts of interest to report.
Frank Schneider, MD

Associate Professor of Pathology
Department of Pathology and Laboratory Medicine
Emory University School of Medicine
Atlanta, Georgia

Frank Schneider, MD, has no relevant conflicts of interest to report.
Conor Ernst Steuer, MD

Assistant Professor
Department of Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Conor Ernst Steuer, MD, has disclosed that he has received consulting fees from Caris, Mirati, and Sanofi and funds for research support from Daiichi.

Program Medium

This program has been made available online.

Related Content

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director Released: June 30, 2022

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director Released: June 28, 2022

Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Phase I CHRYSALIS-2 updates: amivantamab + lazertinib in EGFRm NSCLC after progression with osimertinib and chemotherapy, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings